Patents by Inventor Dexi Yang

Dexi Yang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220235033
    Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XI activation inhibitors.
    Type: Application
    Filed: May 26, 2020
    Publication date: July 28, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Jacqueline D. Hicks, John S. Debenham, Amjad Ali, Lan Wei, Tianying Jian, Dexi Yang, Anthony K. Ogawa, Wenlang Fu, Matthew Lombardo, Rongze Kuang, Meng Yang, Sung-Sau So, Kenneth Ellsworth, Peter Nizner, Daniel A. Tatosian, Robert R. Wilkening, Jun Wang
  • Publication number: 20220144771
    Abstract: The present invention is directed to pyrrolidine compounds which are agonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Application
    Filed: February 11, 2020
    Publication date: May 12, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Stephane L. Bogen, Michael J. Breslin, Dane James Clausen, Anthony Ginnetti, Michael T. Rudd, Shawn J. Stachel, Craig A. Stump, Dexi Yang
  • Publication number: 20220056017
    Abstract: The present invention is directed to bicyclo[4.1.0]heptane pyrrolidine compounds which are agonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Application
    Filed: August 16, 2021
    Publication date: February 24, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Stephane L. BOGEN, Dane James CLAUSEN, Deodial Guy GUIADEEN, Jinsong HAO, Shishi LIN, Michael T. RUDD, Lan WEI, Li XIAO, Dexi YANG
  • Patent number: 11207312
    Abstract: The present invention relates to metallo-?-lactamase inhibitor compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein Z, RA, X1, X2 and R1 are as defined herein. The present invention also relates to compositions which comprise a metallo-?-lactamase inhibitor compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, optionally in combination with a beta lactam antibiotic and/or a beta-lactamase inhibitor. The invention further relates to methods for treating a bacterial infection comprising administering to a patient a therapeutically effective amount of a compound of the invention, in combination with a therapeutically effective amount of one or more ?-lactam antibiotics and optionally in combination with one or more beta-lactamase inhibitor compounds. The compounds of the invention are useful in the methods described herein for overcoming antibiotic resistance.
    Type: Grant
    Filed: July 12, 2018
    Date of Patent: December 28, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Alexander Pasternak, Shuzhi Dong, Jack D. Scott, Haiqun Tang, Zhiqiang Zhao, Dexi Yang, Xin Gu, Jinlong Jiang, Li Xiao
  • Patent number: 11098029
    Abstract: The present invention is directed to 5-alkyl pyrrolidine compounds which are agonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Grant
    Filed: February 11, 2020
    Date of Patent: August 24, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Stephane L. Bogen, Dane James Clausen, Deodial Guy Guiadeen, Michael T. Rudd, Dexi Yang
  • Publication number: 20200375987
    Abstract: The present invention relates to metallo-?-lactamase inhibitor compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein RA, R1, and Z are as defined herein. The present invention also relates to compositions which comprise a metallo-?-lactamase inhibitor compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, optionally in combination with a beta lactam antibiotic and/or a beta-lactamase inhibitor. The invention further relates to methods for treating a bacterial infection comprising administering to a patient a therapeutically effective amount of a compound of the invention, in combination with a therapeutically effective amount of one or more ?-lactam antibiotics and optionally in combination with one or more beta-lactamase inhibitor compounds. The compounds of the invention are useful in the methods described herein for overcoming antibiotic resistance.
    Type: Application
    Filed: December 20, 2018
    Publication date: December 3, 2020
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Alexander Pasternak, Shuzhi Dong, Jack D. Scott, Haiqun Tang, Zhiqiang Zhao, Dexi Yang, Li Xiao, Xin Gu, Jinlong Jiang
  • Publication number: 20200281913
    Abstract: The present invention relates to metallo-?-lactamase inhibitor compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein Z, RA, X1, X2 and R1 are as defined herein. The present invention also relates to compositions which comprise a metallo-?-lactamase inhibitor compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, optionally in combination with a beta lactam antibiotic and/or a beta-lactamase inhibitor. The invention further relates to methods for treating a bacterial infection comprising administering to a patient a therapeutically effective amount of a compound of the invention, in combination with a therapeutically effective amount of one or more ?-lactam antibiotics and optionally in combination with one or more beta-lactamase inhibitor compounds. The compounds of the invention are useful in the methods described herein for overcoming antibiotic resistance.
    Type: Application
    Filed: July 12, 2018
    Publication date: September 10, 2020
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Alexander Pasternak, Shuzhi Dong, Jack D. Scott, Haiqun Tang, Zhiqiang Zhao, Dexi Yang, Xin Gu, Jinlong Jiang, Li Xiao
  • Publication number: 20200255403
    Abstract: The present invention is directed to 5-alkyl pyrrolidine compounds which are agonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Application
    Filed: February 11, 2020
    Publication date: August 13, 2020
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Stephane L. BOGEN, Dane James CLAUSEN, Deodial Guy GUIADEEN, Michael T. RUDD, Dexi YANG
  • Patent number: 10544130
    Abstract: The present invention relates to metallo-?-lactamase inhibitor compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein Z, RA, X1, X2 and R1 are as defined herein. The present invention also relates to compositions which comprise a metallo-?-lactamase inhibitor compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, optionally in combination with a beta lactam antibiotic and/or a beta-lactamase inhibitor. The invention further relates to methods for treating a bacterial infection comprising administering to a patient a therapeutically effective amount of a compound of the invention, in combination with a therapeutically effective amount of one or more ?-lactam antibiotics and optionally in combination with one or more beta-lactamase inhibitor compounds. The compounds of the invention are useful in the methods described herein for overcoming antibiotic resistance.
    Type: Grant
    Filed: January 10, 2019
    Date of Patent: January 28, 2020
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Frank Bennett, Jinlong Jiang, Alexander Pasternak, Shuzhi Dong, Xin Gu, Jack D. Scott, Haiqun Tang, Zhiqiang Zhao, Yuhua Huang, Dexi Yang, Katherine Young, Li Xiao, Zhibo Zhang, Jianmin Fu
  • Publication number: 20190144432
    Abstract: The present invention relates to metallo-?-lactamase inhibitor compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein Z, RA, X1, X2 and R1 are as defined herein. The present invention also relates to compositions which comprise a metallo-?-lactamase inhibitor compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, optionally in combination with a beta lactam antibiotic and/or a beta-lactamase inhibitor. The invention further relates to methods for treating a bacterial infection comprising administering to a patient a therapeutically effective amount of a compound of the invention, in combination with a therapeutically effective amount of one or more ?-lactam antibiotics and optionally in combination with one or more beta-lactamase inhibitor compounds. The compounds of the invention are useful in the methods described herein for overcoming antibiotic resistance.
    Type: Application
    Filed: January 10, 2019
    Publication date: May 16, 2019
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Frank Bennett, Jinlong Jiang, Alexander Pasternak, Shuzhi Dong, Xin Gu, Jack D. Scott, Haiqun Tang, Zhiqiang Zhao, Yuhua Huang, Dexi Yang, Katherine Young, Li Xiao, Zhibo Zhang, Jianmin Fu
  • Patent number: 10227331
    Abstract: The present invention relates to metallo-?-lactamase inhibitor compounds of Formula I: (I) and pharmaceutically acceptable salts thereof, wherein Z, RA, X1, X2 and RB are as defined herein. The present invention also relates to compositions which comprise a metallo-?-lactamase inhibitor compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, optionally in combination with a beta lactam antibiotic and/or a beta-lactamase inhibitor. The invention further relates to methods for treating a bacterial infection comprising administering to a patient a therapeutically effective amount of a compound of the invention, in combination with a therapeutically effective amount of one or more ?-lactam antibiotics and optionally in combination with one or more beta-lactamase inhibitor compounds. The compounds of the invention are useful in the methods described herein for overcoming antibiotic resistance.
    Type: Grant
    Filed: June 24, 2016
    Date of Patent: March 12, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Frank Bennett, Jinlong Jiang, Alexander Pasternak, Shuzhi Dong, Xin Gu, Jack D. Scott, Haiqun Tang, Zhiqiang Zhao, Yuhua Huang, David Hunter, Dexi Yang, Katherine Young, Li Xiao, Zhibo Zhang, Jianmin Fu, Yunfeng Bai, Zhixiang Zheng, Xu Zhang
  • Patent number: 10221163
    Abstract: The present invention relates to metallo-beta-lactamase inhibitor compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein Z, RA, X1, X2 and R1 are as defined herein. The present invention also relates to compositions which comprise a metallo-beta-lactamase inhibitor compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, optionally in combination with a beta-lactam antibiotic and/or a beta-lactamase inhibitor. The invention further relates to methods for treating a bacterial infection comprising administering to a patient a therapeutically effective amount of a compound of the invention, in combination with a therapeutically effective amount of one or more ?-lactam antibiotics and optionally in combination with one or more beta-lactamase inhibitor compounds. The compounds of the invention are useful in the methods described herein for overcoming antibiotic resistance.
    Type: Grant
    Filed: June 24, 2016
    Date of Patent: March 5, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Frank Bennett, Jinlong Jiang, Alexander Pasternak, Shuzhi Dong, Xin Gu, Jack D. Scott, Haiqun Tang, Zhiqiang Zhao, Yuhua Huang, Dexi Yang, Katherine Young, Li Xiao, Zhibo Zhang, Jianmin Fu
  • Publication number: 20180244656
    Abstract: The present invention relates to metallo-beta-lactamase inhibitor compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein Z, RA, X1, X2 and R1 are as defined herein. The present invention also relates to compositions which comprise a metallo-beta-lactamase inhibitor compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, optionally in combination with a beta-lactam antibiotic and/or a beta-lactamase inhibitor. The invention further relates to methods for treating a bacterial infection comprising administering to a patient a therapeutically effective amount of a compound of the invention, in combination with a therapeutically effective amount of one or more ?-lactam antibiotics and optionally in combination with one or more beta-lactamase inhibitor compounds. The compounds of the invention are useful in the methods described herein for overcoming antibiotic resistance.
    Type: Application
    Filed: June 24, 2016
    Publication date: August 30, 2018
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Frank Bennett, Jinlong Jiang, Alexander Pasternak, Shuzhi Dong, Xin Gu, Jack D. Scott, Haiqun Tang, Zhiqiang Zhao, Yuhua Huang, Dexi Yang, Katherine Young, Li Xiao, Zhibo Zhang, Jianmin Fu
  • Publication number: 20180179190
    Abstract: The present invention relates to metallo-?-lactamase inhibitor compounds of Formula I: (I) and pharmaceutically acceptable salts thereof, wherein Z, RA, X1, X2 and RB are as defined herein. The present invention also relates to compositions which comprise a metallo-?-lactamase inhibitor compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, optionally in combination with a beta lactam antibiotic and/or a beta-lactamase inhibitor. The invention further relates to methods for treating a bacterial infection comprising administering to a patient a therapeutically effective amount of a compound of the invention, in combination with a therapeutically effective amount of one or more ?-lactam antibiotics and optionally in combination with one or more beta-lactamase inhibitor compounds. The compounds of the invention are useful in the methods described herein for overcoming antibiotic resistance.
    Type: Application
    Filed: June 24, 2016
    Publication date: June 28, 2018
    Applicant: Marck Sharp & Dohme Corp.
    Inventors: Frank Bennett, Jinlong Jiang, Alexander Pasternak, Shuzhi Dong, Xin Gu, Jack D. Scott, Haiqun Tang, Zhiqiang Zhao, Yuhua Huang, David Hunter, Dexi Yang, Katherine Young, Li Xiao, Zhibo Zhang, Jianmin Fu, Yunfeng Bai, Zhixiang Zheng, Xu Zhang
  • Patent number: 9839642
    Abstract: The present invention relates to compounds of formula I that are metallo-?-lactamase inhibitors, the synthesis of such compounds, and the use of such compounds for use with ?-lactam antibiotics for overcoming resistance.
    Type: Grant
    Filed: May 4, 2015
    Date of Patent: December 12, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Haifeng Tang, Shu-Wei Yang, Mihir Mandal, Jing Su, Guoqing Li, Weidong Pan, Haiqun Tang, Reynalda DeJesus, Jianping Pan, William Hagmann, Fa-Xiang Ding, Li Xiao, Alexander Pasternak, Yuhua Huang, Shuzhi Dong, Dexi Yang
  • Patent number: 9708336
    Abstract: The present invention relates to compounds of formula (I) that are metallo-?-lactamase inhibitors, the synthesis of such compounds, and the use of such compounds for use with ?-lactam antibiotics for overcoming resistance.
    Type: Grant
    Filed: January 16, 2015
    Date of Patent: July 18, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Mihir Mandal, Haifeng Tang, Li Xiao, Jing Su, Guoqing Li, Shu-Wei Yang, Weidong Pan, Haiqun Tang, Reynalda DeJesus, Jacqueline Hicks, Matthew Lombardo, Hong Chu, William Hagmann, Alex Pasternak, Xin Gu, Jinlong Jiang, Shuzhi Dong, Fa-Xiang Ding, Clare London, Dipshikha Biswas, Katherine Young, David N. Hunter, Zhiqiang Zhao, Dexi Yang
  • Publication number: 20170173035
    Abstract: The present invention relates to compounds of formula I that are metallo-?-lactamase inhibitors, the synthesis of such compounds, and the use of such compounds for use with ?-lactam antibiotics for overcoming resistance.
    Type: Application
    Filed: May 4, 2015
    Publication date: June 22, 2017
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Haifeng Tang, Shu-Wei Yang, Mihir Mandal, Jing Su, Guoqing Li, Weidong Pan, Haiqun Tang, Reynalda DeJesus, Jianping Pan, William Hagmann, Fa-Xiang Ding, Li Xiao, Alexander Pasternak, Yuhua Huang, Shuzhi Dong, Dexi Yang
  • Publication number: 20160333021
    Abstract: The present invention relates to compounds of formula (I) that are metallo-?-lactamase inhibitors, the synthesis of such compounds, and the use of such compounds for use with ?-lactam antibiotics for overcoming resistance.
    Type: Application
    Filed: January 16, 2015
    Publication date: November 17, 2016
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Mihir Mandal, Haifeng Tang, Li Xiao, Jing Su, Guoqing Li, Shu-Wei Yang, Weidong Pan, Haiqun Tang, Reynalda DeJesus, Jacqueline Hicks, Matthew Lombardo, Hong Chu, William Hagmann, Alex Pasternak, Xin Gu, Jinlong Jiang, Shuzhi Dong, Fa-Xiang Ding, Clare London, Dipshikha Biswas, Katherine Young, David N. Hunter, Zhiqiang Zhao, Dexi Yang